NICO Corporation has announced that it has seen positive results from initial trials of Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH), comparing the safety, efficacy and economic outcomes of early minimally invasive parafascicular surgery to traditional methods.
The trials were held at the annual American Association of Neurological Surgeons scientific meeting. The comparison looked at early minimally invasive parafascicular surgery (MIPS) with standard medical management based on American Heart Association/American Stroke Association guidelines. Hemorrhagic stroke affects 2 million people each year, and up to 50% of patients die within 30 days, according to a Cision PR Newswire. It's believed that the trial's positive results could affect outcomes for hemorrhagic stroke patients.
"The results of the ENRICH trial are revolutionary and represent an advancement for improving outcomes for the millions of people who suffer hemorrhagic strokes," Jim Pearson, president and CEO of NICO Corporation, told Cision PR Newswire. "For more than a decade, NICO has been committed to delivering the science and innovative tools behind minimally invasive neurosurgery for the ICH population, and ENRICH is the culmination of our mission. We are thrilled to bring these results to the physicians, patients and caregivers of the hemorrhagic stroke community."
ICH is a type of stroke caused by bleeding close to the surface or deep areas of the brain due to a damaged blood vessel in the head. As the amount of blood increases, it can cause brain damage, unconsciousness or death.
As a result, treating hemorrhagic strokes costs the U.S. health care system more than $12 billion each year, and occurrences are expected to rise due to an aging population and the increased use of anticoagulants. NICO Corp. said the positive results of the initial trial "may lead to a superior standard of care," for stroke patients, 50% of whom die within 30 days. Those who survive have a high likelihood of being dependent on others for daily activities and only a small percentage of likelihood of functional independence, according to Cision PR Newswire.
NICO shared the results of the trial at the 2023 Association of Neurological Surgeons annual scientific meeting. NICO said the trial was planned to assess the safety, efficacy and economic outcomes of an early MIPS technique in 300 patients with spontaneous hemorrhagic stroke. The trial was randomized, adaptive and conducted across 37 participating sites.
